Steven Nissen News
-
Boston Scientific Corp.’s Watchman device, designed to help prevent strokes in patients with an erratic heartbeat, was safer than previously thought in a second study requested by U.S. regulators, researchers said.
-
A Swedish pharmaceutical company with no products on the market is hatching a drug-testing shortcut to catapult its experimental cholesterol pill into a potential $1.3 billion-a-year seller.
-
Merck & Co. won’t seek U.S. marketing approval for its good cholesterol drug Tredaptive after a key study showed it ineffective and potentially harmful.
-
GlaxoSmithKline Plc’s Avandia may face tougher scrutiny from a U.S. advisory panel reviewing whether the diabetes pill should be pulled from the market than a similar analysis in 2007, doctors said.
-
GlaxoSmithKline Plc’s Avandia was linked to heart attacks and other cardiovascular complications in two new studies that the authors say should prompt U.S. regulators to pull the diabetes drug from the market.
-
A U.S. advisory panel’s call for stronger warnings about heart risks tied to GlaxoSmithKline Plc ’s diabetes drug Avandia may further erode sales that had already been dropping over the last two years.
-
Roche Holding AG is planning a final-stage trial of a drug that taps into a gene mutation to lower cholesterol and heart attack risk beyond what statins such as Pfizer Inc.’s $9.6 billion-selling Lipitor can do.
-
Amgen Inc., the world’s largest biotechnology company, is developing a new anti-cholesterol medicine by 2015 that it sees as its best shot to offset reduced sales when its popular anemia drugs lose exclusivity.
-
A study of an experimental blood thinner from Merck & Co. showed that while the drug helped thwart heart attacks it raised the risk of brain bleeding, a side effect that could stymie its approval.
-
Philadelphia Phillies pinch-hitter Greg Dobbs says he has no idea whether energy-enhancing jewelry that’s being worn by athletes from Little Leaguers to basketball icon LeBron James really works.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page